ASCO 2020：11项中国研究表现出色口头报告，17项Poster报告

所致全球新的冠疫情所致到影响，原订于5同年29日~6同年2日在芝加哥举行的美国临床研究学会（ASCO）年会今年将首次以终点站上方式举办地，这是目前最大规模的终点站上盛会。今天，决议的概述题目公布，共五103个sessions，中所国共五有11项研究工作入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

芳基替尼或拉帕替尼加卡培他滨常用HER2+结核乳腺乳癌（PHOEBE）：一项III期随机检验。

演奏会：结核乳腺乳癌

写作者：中所国医学科学院病房徐兵河任教、马飞任教，山东大学原为病房胡夕春任教等

概述号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可疗程三不同之处性乳腺乳癌国际标准疗程后卡培他滨确保节拍抗生素的III期检验（SYSUCC-001）。

演奏会：乳腺乳癌—周围内/周围/主要用途疗程

写作者：中所山大学卫生保健为中所心王于树森任教等

概述号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用结核脑部的变异不同之处来得出脑部脊液中所循环DNA样品的随机性: 新的工具对抗老对手

演奏会：新的工具解决老问题

写作者：朱美芹 朱德兰等

概述号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

伊克非尼对奈及利亚拉非尼作为中所晚期肝蛋白质乳癌的一终点站疗程：一项停止使用标签、随机、多为中所心II/III期检验。

演奏会：消化系统乳癌—小肠输尿管、十二指肠和实为

写作者：重庆大学华西病房毕锋任教、中所国老百姓解放军淮海病房秦叔逵任教等

概述号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中所国中所晚期肝乳癌症状阿帕替尼二终点站疗程：一项随机、口服对照、CPAIII期研究工作

演奏会：消化系统乳癌—小肠输尿管、十二指肠和实为

写作者：中所国老百姓解放军淮海病房秦叔逵任教、重庆大学华西病房朱秋任教等

概述号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

中所晚期继发卵巢乳癌二次蛋白质减灭术的一项随机III期检验：SOC1 / SGOG-OV2。

简介：妇产科乳帕金森氏症

写作者：山东大学原为中所山病房臧荣余任教等

概述：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈乳癌根治性乳房外科手术后主要用途疗程中所的序贯放抗生素对比单独化疗或同步放抗生素（STARS研究工作）：一项随机、对照、停止使用标签的III期检验。

决议：妇产科乳帕金森氏症

写作者：中所山大学卫生保健为中所心黄鹤任教、刘继红任教等

概述号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：主要用途吉非替尼对比抗生素常用可切除的EGFR基因型的N1-N2期NSCLC-随机III期临床研究的最终总体共五存深入研究。

简介：膀胱乳癌—非小蛋白质周围内-周围/小蛋白质/其他颈部

写作者：潮州市老百姓病房吴一龙任教等

概述号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR基因型寡转移非小蛋白质膀胱乳癌症状一终点站过氧化物过氧化物肽合组或不合组更进一步前终点站周围内化疗：III期停止使用标签临床研究随机检验（SINDAS）的中所期结果（NCT02893332）。

简介：膀胱乳癌-非小蛋白质转移

写作者：四川省老百姓病房曾铭任教等

概述：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序性被害-1（PD-1）的人源化IgG4单克隆抗体合组阿昔替尼常用结核黏膜阿兹海默症状的Ib期研究工作的总共五存期和动物研究课题深入研究。

简介：阿兹海默/白内障

写作者：北京大学病房郭军、盛锡楠任教等

概述：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全性和结果：通用CAR-T蛋白质首次体内检验疗程病情恶化/难治性T蛋白质急性淋巴蛋白质癌症（r/r T-ALL）的安全性和。决议：开发新的中所的疗程技术-免疫疗程。写作者：朱森欣等概述：3013广告：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在中所晚期输尿管上皮细胞蛋白质乳癌症状中所的运用于：一项随机的停止使用标签II期检验（ORIENT-2）。决议：消化系统乳癌-小肠输尿管乳癌、癌症和实为道乳癌写作者：徐建明任教等概述：4511广告：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T蛋白质对髓母蛋白质瘤的禁绝性疗程决议：中所枢神经系统写作者：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、徐旭东概述：2522广告。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在中所晚期错配修复缺陷症状中所的运用于决议：开发新的中所的疗程学-免疫疗程写作者：沈琳任教等概述：3021广告。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 其会CD7-CART疗程病情恶化/难治性ACUTE淋巴蛋白质癌症/淋巴瘤的首例体内临床研究决议: 开发新的性疗程学-免疫疗程写作者简介：张明志，白水等概述：3026广告: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度酮（T）合组应常用中所晚期对等瘤症状的Ib期研究工作决议：发展性疗程学--小分子靶向肽和动物学写作者：龚继芳，沈琳任教等概述：3523广告：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin合组吲哚和nedaplatin疗程继发或结核输尿管上皮细胞蛋白质乳癌（ESCC）症状的II期研究工作。决议：消化系统乳癌-小肠输尿管、十二指肠和实为道乳癌的研究工作写作者：王于志强，朱玉红，王于德申，王于凤华，任超，谭琼 王于志强、朱玉红、王于德深、王于凤华、任超、谭琼概述：4522广告：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.决议：消化系统乳癌-小肠输尿管乳癌、癌症和实为管乳癌的二终点站疗程写作者：宋艳等概述：4524广告：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿外体网状RNA权重常用初始活检时样品高等级乳癌的尿外体网状RNA权重：一项多为中所心的回顾性研究工作决议：泌尿生殖系统乳帕金森氏症---乳癌、乳腺乳癌和乳癌写作者简介：Liaoyuan Li等概述：5522广告。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 周围内中所晚期宫颈乳癌并发抗生素后的主要用途抗生素决议: 妇产科乳帕金森氏症写作者简介： 朱珉珉等概述：6031广告：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗程甲状腺髓性乳癌的相关性：基于ALTER01031检验的深入研究。会福州话：鳞状写作者：唐山市病房高明任教概述：6526广告。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和平均年龄对安洛替尼疗程后症状结局的所致到影响: ALTER01031的亚组深入研究决议：鳞状写作者：唐山市病房高明任教概述：6527广告。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA深入研究得出I-IIIA期非小蛋白质膀胱乳癌（NSCLC）症状术后病情恶化: GASTO1035和GASTO1018的结果决议：膀胱乳癌-非小蛋白质周围内-周围性/小蛋白质/小蛋白质/其他胸科乳帕金森氏症写作者：Si-Yu Wang等概述：9023广告：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小蛋白质膀胱乳癌（NSCLC）中所EGFR过氧化物过氧化物肽的新的型耐药机制决议:膀胱乳癌-非小蛋白质结核膀胱乳癌写作者简介：徐昕，金大姐，满宇，欧西厢记，华宝，薛武，杨少，范敏 徐昕、金大姐、满宇、欧西厢记、华宝、薛武、杨绍、范敏概述：9528广告：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1检验中所中所晚期阿兹海默总共五存的替代终点决议：阿兹海默/白内障写作者：聂润聪，袁书强，朱元芳，陈英波，周志伟 聂润聪、袁书强、朱元芳、陈英波、周志伟概述：10030广告：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗程病情恶化或结核细菌性恶性骨症状的II期研究工作决议： 肉瘤写作者：唐丽娜，牛晓辉，朱先念，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王于振、蔡启庆、涂崇奇、范正福、杨瑶概述：11525广告。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 全面性评分安罗替尼在中所晚期肉瘤症状多终点站疗程中所的安全性和。决议：肉瘤写作者：姚伟涛，来由强，张鹏，朱森，杜新的辉，田志浩，牛晓颖 姚伟涛、来由强、张鹏、王于鑫、杜鑫辉、田志超、牛晓英概述：11526广告：414